Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Rifaximin: In vitro and in vivo Antibacterial Activity – A Review

Jiang Z.D.a · DuPont H.L.a,b

Author affiliations

aCenter for Infectious Diseases, University of Texas-Houston School of Public Health, bSt. Luke’s Episcopal Hospital and Baylor College of Medicine, Houston, Tex., USA

Related Articles for ""

Chemotherapy 2005;51(suppl 1):67–72

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: April 11, 2005
Issue release date: April 2005

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 4

ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)

For additional information: https://www.karger.com/CHE

Abstract

In vitro inhibitory activity of rifaximin is directed against Gram-positive and Gram-negative, aerobic and anaerobic bacteria. It is effective in the treatment of gastrointestinal infections when given orally because of the high concentration of the drug remaining in the gut lumen. Laboratory investigations have been carried out to assess the in vitro activity of rifaximin on different bacterial strains isolated from both human and domestic animals. The objective of this project is to review the in vitro and in vivo activity of rifaximin against bacterial infection with Gram-negative rods, Gram-positive rods and Gram-positive cocci and their resistance to rifaximin. The available data suggest that rifaximin is active in vitro and in vivo in the treatment of bacterial infection of adults and children.

© 2005 S. Karger AG, Basel


References

  1. Marchi E, Mascellani G, Montecchi L, Brufani M, Cellai L: L/105, a new semisynthetic derivative of rifamycin SV, synthesis and structure-activity relationship. Chemioterapia 1983;2:38.
  2. Venturini AP: L/105: Report on pharmacokinetics in rats, dogs, after oral administration and adverse reactions. Proceedings of III Mediterranean Congress of Chemotherapy, 21–24 September 1982 – Dubrovnik, Yugoslavia. Chemioterapia 1983;2(suppl 5):162–163.
  3. Gillis J, Brogden R: Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995;49:467–484.
  4. Corazza GR, Ventrucci M, Strocchi A, Sorge M, Pranzo L, Pezzilli R, Gasbarrini G: Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin. J Int Med Res 1988;16:312–316.
  5. Jiang ZD, Ke S, Palazzini E, Riopel L, DuPont HL: In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000;44:2205–2206.
  6. Venturini AP: Pharmacokinetics of L/105, a new rifamycin, in rats and dogs, after oral administration. Chemotherapy 1983;29:1–3.
  7. DuPont HL, Jiang ZD, Ericsson CD, Mathewson JJ, Adachi J, Palazzini E, Riopel LM, Ashley D, Martinez-Sandoval F: Rifaximin for the treatment of travelers’ diarrhea: A randomized, double-blind clinical trial versus ciprofloxacin. Clin Infect Dis, submitted.
  8. Sanfilippo A, Raciti Longo G, Raciti Longo A: Clinical experience with rifaximin in pediatric diarrhea syndromes. Med Praxis 1984;5:375–379.
  9. De-Leo C, Eftimiadi C, Schito GC: Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 1986;12:979–981.
  10. von Sonnenburg F, Tornieporth N, Waiyaki P, Lowe B, Peruski LF Jr, DuPont HL, Mathewson JJ, Steffen R: Risk and aetiology of diarrhoea at various tourist destinations. Lancet 2000;356:133–134.
  11. Jiang ZD, Lowe B, Vernekar MP, Ashley D, Steffen R, Tornieporth N, von Sonnenburg F, Svennerholm AM, Waiyaki P, DuPont HL: Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J Infect Dis 2002;185:497–502.
  12. Adachi J, Jiang ZD, Mathewson JJ, Verenkar MP, Thompson S, Martinez-Sandoval F, Steffen R, Ericsson CD, DuPont HL: Enteroaggregative Escherichia coli as a major etiologic agent in traveler’s diarrhea in 3 regions of the world. Clin Infect Dis 2001;32:1706–1709.
  13. DuPont HL, Ericsson CD, Mathewson JJ, de la Cabada FJ, Conrad D: Oral aztreonam, a poorly absorbed yet effective therapy for bacterial diarrhea in US travelers to Mexico. JAMA 1992;267:1932–1935.
  14. Ericsson CD, DuPont HL, Sullivan P, Galindo E, Evans DG, Evans DJ Jr: Bicozamycin, a poorly absorbable antibiotic, effectively treats travelers’ diarrhea. Ann Intern Med 1983;98:20–25.
  15. DuPont HL, Ericsson CD, Mathewson JJ, Palazzini E, DuPont MW, Jiang ZD, Mosavi A, de la Cabada FJ: Rifaximin: A nonabsorbed antimicrobial in the therapy of travelers’ diarrhea. Digestion 1998;59:708–714.
  16. Gomi H, Jiang ZD, Adachi JA, Ashley D, Lowe B, Verenkar MP, Steffen R, DuPont HL: In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing travelers’ diarrhea in four geographic regions. Antimicrob Agents Chemother 2001;45:212–216.
  17. Sierra JM, Ruiz J, Navia MM, Vargas M, Gascon J, Vila J: In vitro activity of rifaximin against enteropathogens producing traveler’s diarrhea. Antimicrob Agents Chemother 2001;45:643–644.
  18. Mignini F, Falcioni E, Prenna M, Santacroce F, Ripa S: Antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejuni and Yersinia spp. J Chemother 1989;1:220–222.
  19. Ng BL, Ng HC, Goh KT, Ho B: Helicobacter pylori in familial clusters based on antibody profile. FEMS Immunol Med Microbiol 2001;30:139–142.
  20. Megraud F, Bouffant F, Camou-Juncas C: In vitro activity of rifaximin against Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1994;13:184–186.
  21. Dell’Anna A, Azzarone P, Ferrieri A: A randomized openly comparative study between rifaximin suspension versus rifaximin pills for the eradication of Helicobacter pylori. Eur Rev Med Pharmacol Sci 1999;3:105–110.
  22. Raviglione MC, Snider DE, Kochi A: Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 1995;273:241–242.
  23. Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW: The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993;328:521–526.
  24. Lamanna A, Orsi A: In vitro activity of rifaximin and rifampicin against some anaerobic bacteria. Chemioterapia 1984;3:365–367.
  25. Soro O, Pesce A, Raggi M, Debbia E, Shito C: Selection of rifampicin-resistant Mycobacterium tuberculosis does not occur in the presence of low concentrations of rifaximin. Clin Microbiol Infect 1997;3:147–151.
  26. Lucchesi M, Marchi E, Venturini AP: Antimycobacterial activity of rifaximin (L/105) in experimental tuberculosis in the Guinea pig. Chemioterapia 1984;3:371–372.
  27. Eftimiadi C, Deleo C, Schito GC: Treatment of hepatic encephalopathy with L/105, a new non-absorbable rifamycin. Drugs Exp Clin Res 1984;10:691–696.
  28. Marchese A, Salerno A, Pesce A, Debbia EA, Schito GC: In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy 2000;46:253–266.
  29. Crossley IR, Wardle EN, Williams R: Biochemical mechanisms of hepatic encephalopathy. Clin Sci (Lond) 1983;64:247–252.
  30. Hoover W, Gerlach E, Hoban D, Eliopoulos G, Pfaller M, Jones R: Antimicrobial activity and spectrum of rifaximin. A new topical rifamycin derivative. Diagn Microbiol Infect Dis 1993;16:111–118.
  31. Venturini AP, Marchi E: In vitro and in vivo evaluation of L/105, a new topical intestinal rifamycin. Chemioterapia 1986;5:257–262.
  32. DuPont HL, Reves R, Galindo R, Sullivan P, Wood L, Mendiola J: Treatment of travelers’ diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone. N Engl J Med 1982;307:841–844.
  33. Steffen R, Sack DA, Riopel L, Jiang Z-D, Sturchler M, Ericsson CD, Lowe B, Waiyaki P, White M, DuPont HL: Therapy of travelers’ diarrhea with rifaximin on various continents. Am J Gastroenterol 2003;98:1073–1078
  34. Amenta M, Dalle Nogare ER, Colomba D, Prestileo TS, Di Lorenzo F, Fundaro S, Colomba A, Ferrieri A: Intestinal protozoa in HIV-infected patients: effect of rifaximin in Cryptosporidium parvum and Blastocystis hominis infections. J Chemother 1999;11:391–395.
  35. Brigidi P, Swennen E, Rizzello F, Bozzolasco M, Matteuzzi D: Effect of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother (Florence) 2002;14(3):290–295.
  36. Neu HC: The crisis in antibiotic resistance. Science 1992;257:1064–1073.
  37. DuPont HL, Jiang ZD: Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect 2004;10:1009–1011.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: April 11, 2005
Issue release date: April 2005

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 4

ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)

For additional information: https://www.karger.com/CHE


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.